Addition of tiagabine to second-generation antipsychotics in the treatment of recent-onset schizophrenia by modification of developmental reorganization of the prefrontal cortex
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Tiagabine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 27 Jan 2025 Planned End Date changed from 1 Sep 2024 to 1 Sep 2026.
- 27 Jan 2025 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2026.
- 05 Jun 2023 Planned End Date changed from 1 Sep 2022 to 1 Sep 2024.